PDF herunterladen
J Reconstr Microsurg 2018; 34(07): 537-548
DOI: 10.1055/s-0038-1642023
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chronic Nerve Compression Accelerates the Progression of Diabetic Peripheral Neuropathy in a Rat Model: A Study of Gene Expression Profiling

Yiji Tu   *
1   Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai, China
2   Joseph M. Still Burn and Reconstructive Center, Jackson, Mississippi
,
Zenggan Chen   *
1   Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai, China
,
Junda Hu
1   Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai, China
,
Zuoyou Ding
1   Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai, China
,
William C. Lineaweaver
2   Joseph M. Still Burn and Reconstructive Center, Jackson, Mississippi
,
A. Lee Dellon
3   Department of Plastic Surgery, Johns Hopkins University, Baltimore, Maryland
,
Feng Zhang
1   Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai, China
2   Joseph M. Still Burn and Reconstructive Center, Jackson, Mississippi
› Institutsangaben Funding This work was supported by a grant from the Recruitment Program of Global Experts in Fudan University (number: EZF152501).
Weitere Informationen

Publikationsverlauf

26. September 2017

06. März 2018

Publikationsdatum:
25. April 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Objective This article investigates the role of chronic nerve compression in the progression of diabetic peripheral neuropathy (DPN) by gene expression profiling.

Methods Chronic nerve compression was created in streptozotocin (STZ)-induced diabetic rats by wrapping a silicone tube around the sciatic nerve (SCN). Neurological deficits were evaluated using pain threshold test, motor nerve conduction velocity (MNCV), and histopathologic examination. Differentially expressed genes (DGEs) and metabolic processes associated with chronic nerve compression were analyzed.

Results Significant changes in withdrawal threshold and MNCV were observed in diabetic rats 6 weeks after diabetes induction, and in DPN rats 4 weeks after diabetes induction. Histopathologic examination of the SCN in DPN rats presented typical changes of myelin degeneration in DPN. Function analyses of DEGs demonstrated that biological processes related to inflammatory response, extracellular matrix component, and synaptic transmission were upregulated after diabetes induction, and chronic nerve compression further enhanced those changes. While processes related to lipid and glucose metabolism, response to insulin, and apoptosis regulation were inhibited after diabetes induction, chronic nerve compression further enhanced these inhibitions.

Conclusion Our study suggests that additional silicone tube wrapping on the SCN of rat with diabetes closely mimics the course and pathologic findings of human DPN. Further studies are needed to verify the effectiveness of this rat model of DPN and elucidate the roles of the individual genes in the progression of DPN.

Keywords

diabetes - peripheral neuropathy - DNA microarray

* Yiji Tu and Zenggan Chen contributed equally to the study and should be the co-first authors.


 

  • References

  • 1 Won JC, Park TS. Recent advances in diagnostic strategies for diabetic peripheral neuropathy. Endocrinol Metab (Seoul) 2016; 31 (02) 230-238
    CrossrefPubMedGoogle Scholar
  • 2 Sanada M, Matsui M, Yasuda H. Pathogenesis of diabetic neuropathy [in Japanese]. Nihon Rinsho 2016; 74 (Suppl. 02) 223-228
    PubMedGoogle Scholar
  • 3 Upton AR, McComas AJ. The double crush in nerve entrapment syndromes. Lancet 1973; 2 (7825): 359-362
    PubMedGoogle Scholar
  • 4 Dahlin LB, Meiri KF, McLean WG, Rydevik B, Sjöstrand J. Effects of nerve compression on fast axonal transport in streptozotocin-induced diabetes mellitus. An experimental study in the sciatic nerve of rats. Diabetologia 1986; 29 (03) 181-185
    CrossrefPubMedGoogle Scholar
  • 5 Dellon AL, Mackinnon SE. Chronic nerve compression model for the double crush hypothesis. Ann Plast Surg 1991; 26 (03) 259-264
    CrossrefPubMedGoogle Scholar
  • 6 Sessions J, Nickerson DS. Biologic basis of nerve decompression surgery for focal entrapments in diabetic peripheral neuropathy. J Diabetes Sci Technol 2014; 8 (02) 412-418
    CrossrefPubMedGoogle Scholar
  • 7 Anderson JC, Nickerson DS, Tracy BL, Paxton RJ, Yamasaki DS. Acute improvement in intraoperative EMG following common fibular nerve decompression in patients with symptomatic diabetic sensorimotor peripheral neuropathy: 1. EMG results. J Neurol Surg A Cent Eur Neurosurg 2017; 78 (05) 419-430
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Zhang W, Zhong W, Yang M, Shi J, Guowei L, Ma Q. Evaluation of the clinical efficacy of multiple lower-extremity nerve decompression in diabetic peripheral neuropathy. Br J Neurosurg 2013; 27 (06) 795-799
    CrossrefPubMedGoogle Scholar
  • 9 Melenhorst WB, Overgoor ML, Gonera EG, Tellier MA, Houpt P. Nerve decompression surgery as treatment for peripheral diabetic neuropathy: literature overview and awareness among medical professionals. Ann Plast Surg 2009; 63 (02) 217-221
    CrossrefPubMedGoogle Scholar
  • 10 Macaré van Maurik JF, van Hal M, van Eijk RP, Kon M, Peters EJ. Value of surgical decompression of compressed nerves in the lower extremity in patients with painful diabetic neuropathy: a randomized controlled trial. Plast Reconstr Surg 2014; 134 (02) 325-332
    CrossrefPubMedGoogle Scholar
  • 11 Pande M, Hur J, Hong Y. , et al. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. Diabetes 2011; 60 (07) 1981-1989
    CrossrefPubMedGoogle Scholar
  • 12 O'Brien PD, Hur J, Hayes JM, Backus C, Sakowski SA, Feldman EL. BTBR ob/ob mice as a novel diabetic neuropathy model: neurological characterization and gene expression analyses. Neurobiol Dis 2015; 73: 348-355
    CrossrefPubMedGoogle Scholar
  • 13 Zhu Q, Gu JH, Zhu HY, Xu JL. Identification of differentially expressed genes in dorsal root ganglion in early diabetic rats. Neurosci Bull 2008; 24 (04) 219-224
    CrossrefPubMedGoogle Scholar
  • 14 Rojewska E, Korostynski M, Przewlocki R, Przewlocka B, Mika J. Expression profiling of genes modulated by minocycline in a rat model of neuropathic pain. Mol Pain 2014; 10: 47
    PubMedGoogle Scholar
  • 15 Malik RA. Pathology of human diabetic neuropathy. Handb Clin Neurol 2014; 126: 249-259
    PubMedGoogle Scholar
  • 16 Herder C, Brunner EJ, Rathmann W. , et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32 (03) 421-423
    CrossrefPubMedGoogle Scholar
  • 17 Spranger J, Kroke A, Möhlig M. , et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52 (03) 812-817
    CrossrefPubMedGoogle Scholar
  • 18 Bierhaus A, Haslbeck KM, Humpert PM. , et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114 (12) 1741-1751
    CrossrefPubMedGoogle Scholar
  • 19 Mu ZP, Wang YG, Li CQ. , et al. Association between tumor necrosis factor-α and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis. Mol Neurobiol 2017; 54 (02) 983-996
    CrossrefPubMedGoogle Scholar
  • 20 Valsecchi AE, Franchi S, Panerai AE, Rossi A, Sacerdote P, Colleoni M. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur J Pharmacol 2011; 650 (2–3): 694-702
    CrossrefPubMedGoogle Scholar
  • 21 Price SA, Zeef LA, Wardleworth L, Hayes A, Tomlinson DR. Identification of changes in gene expression in dorsal root ganglia in diabetic neuropathy: correlation with functional deficits. J Neuropathol Exp Neurol 2006; 65 (07) 722-732
    CrossrefPubMedGoogle Scholar
  • 22 Lee SW, Song KE, Shin DS. , et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005; 69 (02) 175-179
    CrossrefPubMedGoogle Scholar
  • 23 Kuhad A, Singh P, Chopra K. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain. Expert Opin Ther Targets 2015; 19 (02) 177-185
    CrossrefPubMedGoogle Scholar
  • 24 Faissner A. The tenascin gene family in axon growth and guidance. Cell Tissue Res 1997; 290 (02) 331-341
    CrossrefPubMedGoogle Scholar
  • 25 Neidhardt J, Fehr S, Kutsche M, Löhler J, Schachner M. Tenascin-N: characterization of a novel member of the tenascin family that mediates neurite repulsion from hippocampal explants. Mol Cell Neurosci 2003; 23 (02) 193-209
    CrossrefPubMedGoogle Scholar
  • 26 Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58 (10) 2376-2385
    CrossrefPubMedGoogle Scholar
  • 27 Hur J, Sullivan KA, Pande M. , et al. The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain 2011; 134 (Pt 11): 3222-3235
    CrossrefPubMedGoogle Scholar
  • 28 Luo L, Zhou WH, Cai JJ. , et al. Gene expression profiling identifies downregulation of the neurotrophin-MAPK signaling pathway in female diabetic peripheral neuropathy patients. J Diabetes Res 2017; 2017: 8103904
    PubMedGoogle Scholar